Itraconazole



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 22.5%
Drug Use For Unknown Indication 10.4%
Prophylaxis 9.7%
Antifungal Prophylaxis 9.0%
Bronchopulmonary Aspergillosis 7.9%
Aspergillosis 5.0%
Onychomycosis 4.4%
Histoplasmosis 4.4%
Fungal Infection 3.6%
Hypertension 2.9%
Diffuse Large B-cell Lymphoma 2.8%
Acute Lymphocytic Leukaemia 2.7%
Bronchopulmonary Aspergillosis Allergic 2.5%
Systemic Mycosis 2.1%
Cystic Fibrosis 2.0%
Nail Tinea 1.8%
Asthma 1.7%
Acute Myeloid Leukaemia 1.6%
Immunosuppression 1.6%
Multiple Myeloma 1.6%
Drug Interaction 19.6%
Drug Ineffective 12.7%
Death 7.6%
Bronchopulmonary Aspergillosis 4.3%
Pyrexia 4.3%
Rhabdomyolysis 4.3%
Tremor 4.3%
Ileus Paralytic 4.0%
Pneumonia 4.0%
Rash 4.0%
Neurotoxicity 3.6%
Respiratory Failure 3.6%
Epilepsy 3.3%
Neuropathy Peripheral 3.3%
Cholestasis 2.9%
Drug Resistance 2.9%
Electrocardiogram Qt Prolonged 2.9%
Myalgia 2.9%
Oedema Peripheral 2.9%
Candida Infection 2.5%
Secondary
Burkitt's Lymphoma 13.7%
Prophylaxis 12.8%
Product Used For Unknown Indication 12.2%
Drug Use For Unknown Indication 11.3%
Antifungal Prophylaxis 6.4%
Bronchopulmonary Aspergillosis 6.2%
Aspergillosis 4.5%
Immunosuppression 4.2%
Bronchopulmonary Aspergillosis Allergic 3.3%
Phaehyphomycosis 3.1%
Fungal Infection 2.8%
Onychomycosis 2.6%
Acute Myeloid Leukaemia 2.4%
Asthma 2.3%
Pneumonia 2.3%
Diffuse Large B-cell Lymphoma 2.0%
Keratitis Fungal 2.0%
Systemic Mycosis 2.0%
Hypertension 2.0%
Atypical Mycobacterial Infection 1.9%
Renal Impairment 11.7%
Drug Interaction 9.6%
Tremor 6.5%
Death 6.2%
Ubiquinone Decreased 5.8%
Drug Ineffective 5.2%
Rhabdomyolysis 5.2%
Hepatic Function Abnormal 4.8%
Pyrexia 4.8%
Renal Failure 4.8%
Interstitial Lung Disease 4.5%
White Blood Cell Count Decreased 4.5%
Ileus Paralytic 3.8%
Bronchopulmonary Aspergillosis 3.4%
Drug Resistance 3.4%
Oedema Peripheral 3.4%
Haemolytic Anaemia 3.1%
Neutrophil Pelger-huet Anomaly Present 3.1%
Pericarditis 3.1%
Systemic Mycosis 3.1%
Concomitant
Product Used For Unknown Indication 24.1%
Prophylaxis 17.7%
Infection Prophylaxis 7.2%
Aplastic Anaemia 6.3%
Drug Use For Unknown Indication 5.8%
Acute Myeloid Leukaemia 4.5%
Antifungal Prophylaxis 4.5%
Prophylaxis Against Graft Versus Host Disease 4.3%
Multiple Myeloma 3.7%
Premedication 3.6%
Bone Marrow Conditioning Regimen 3.6%
Hiv Infection 3.4%
Antiviral Prophylaxis 2.0%
Prophylaxis Against Gastrointestinal Ulcer 1.6%
Hypertension 1.5%
Constipation 1.5%
Antibiotic Prophylaxis 1.3%
Acute Lymphocytic Leukaemia 1.2%
Myelodysplastic Syndrome 1.1%
Fungal Infection 1.1%
White Blood Cell Count Decreased 15.2%
Pyrexia 8.7%
Sepsis 8.3%
Pneumonia 7.4%
Thrombocytopenia 7.3%
Uveitis 5.0%
Platelet Count Decreased 4.7%
Febrile Neutropenia 4.6%
Vomiting 4.6%
Drug Ineffective 4.2%
Renal Failure Acute 3.6%
Venoocclusive Liver Disease 3.6%
Respiratory Failure 3.3%
Renal Failure 3.0%
Stomatitis 3.0%
Acute Graft Versus Host Disease 2.9%
Pancytopenia 2.9%
Interstitial Lung Disease 2.7%
Renal Impairment 2.6%
Graft Versus Host Disease 2.5%
Interacting
Product Used For Unknown Indication 17.9%
Acute Lymphocytic Leukaemia 9.0%
Drug Use For Unknown Indication 6.3%
Fungal Infection 6.3%
Atrial Fibrillation 6.0%
Immunosuppressant Drug Therapy 5.6%
Atypical Mycobacterial Infection 5.0%
Bronchopulmonary Aspergillosis 5.0%
Mycobacterium Avium Complex Infection 4.3%
Antifungal Prophylaxis 4.0%
Heart Rate Abnormal 4.0%
Heart Rate Increased 4.0%
Prophylaxis 4.0%
Bronchial Secretion Retention 3.0%
Fungaemia 3.0%
Systemic Candida 3.0%
Scedosporium Infection 2.7%
Asthma 2.3%
Hypertension 2.3%
Obsessive-compulsive Disorder 2.3%
Drug Interaction 35.5%
Idiopathic Pneumonia Syndrome 6.6%
Hypotension 5.3%
Ileus Paralytic 5.3%
Cardiac Arrest 3.9%
Staphylococcal Sepsis 3.9%
Tuberculosis 3.9%
Ubiquinone Decreased 3.9%
Blood Creatine Phosphokinase Increased 2.6%
Drug Toxicity 2.6%
Histoplasmosis 2.6%
Hyperglycaemia 2.6%
Hypertension 2.6%
Multiple Myeloma 2.6%
Myopathy 2.6%
Neuropathy Peripheral 2.6%
Oedema Peripheral 2.6%
Progressive Multifocal Leukoencephalopathy 2.6%
Pulmonary Alveolar Haemorrhage 2.6%
Swelling 2.6%